Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an update.
Botanix Pharmaceuticals has corrected its previous announcement regarding the number of patients receiving Sofdra prescriptions. From January to June 2025, 7,989 patients received filled prescriptions, with 10,028 new patient arrivals in the same period. The company emphasizes that filled prescriptions are a key metric for recognizing sales, aligning with industry norms where 90% of new patients are expected to fill their prescriptions. This update reflects Botanix’s commitment to transparency and its strategic focus on Sofdra’s market penetration, which is crucial for its growth in the dermatology sector.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a clinical dermatology company based in Philadelphia and Phoenix, specializing in the development of dermatological treatments. The company has received FDA approval for its lead product, Sofdra, which is a novel treatment for primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating. Sofdra is the first new chemical entity approved by the FDA for this condition, offering a safe and effective solution for patients who previously had limited treatment options.
Average Trading Volume: 9,378,389
Technical Sentiment Signal: Sell
Current Market Cap: A$607.9M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.